5-LOX in Sepsis and Inflammation: A Survey

www.surveyx.cn

Abstract

This survey paper explores the pivotal role of 5-lipoxygenase (5-LOX) in the biosynthesis of leukotrienes, key inflammatory mediators involved in immune responses and the pathophysiology of conditions such as sepsis and chronic inflammation. The paper examines the biochemical pathways of leukotriene synthesis, emphasizing the critical influence of 5-LOX on macrophage activity and its dual role in both acute and chronic inflammatory contexts. Key findings highlight the enzyme's involvement in inflammatory diseases, including neuroinflammation and tumor-associated inflammation, and its potential as a therapeutic target. The survey underscores the complexity of leukotriene signaling pathways and their interactions with other inflammatory mediators, presenting challenges and opportunities for therapeutic interventions. The role of 5-LOX in sepsis is scrutinized, revealing its contribution to immune dysregulation and disease progression. The paper identifies significant knowledge gaps in current sepsis research, emphasizing the need for advanced computational models and personalized medicine approaches to improve diagnostic accuracy and treatment efficacy. Therapeutic implications are discussed, focusing on the modulation of macrophage-leukotriene interactions and the development of targeted therapies that exploit macrophage plasticity. The survey concludes by outlining future research directions, advocating for a multidisciplinary approach to enhance our understanding of 5-LOX and leukotriene pathways, ultimately aiming to improve patient outcomes in inflammatory and immune-related diseases.

1 Introduction

1.1 Relevance of 5-LOX to Sepsis and Inflammation

5-lipoxygenase (5-LOX) is a pivotal enzyme in leukotriene synthesis, which are potent inflammatory mediators involved in acute and chronic inflammatory responses. Its role in sepsis is particularly significant, as 5-LOX modulates immune responses by catalyzing the production of leukotrienes, notably leukotriene B4 (LTB4), crucial for neutrophil recruitment and activation, thereby exacerbating inflammation [1]. In sepsis, characterized by systemic inflammation and organ dysfunction due to an aberrant host response to infection [2], 5-LOX influences the pathological interactions between immune cells and tissues, contributing to disease progression [3].

The inflammatory cascade mediated by 5-LOX includes not only LTB4 but also cysteinyl leukotrienes (cysLTs), which are essential in eosinophil biology and inflammatory responses [4]. This is particularly relevant in acute inflammatory scenarios, where an unchecked immune response can have severe consequences, as seen in sepsis [3]. Additionally, 5-LOX activity correlates with systemic effects in chronic inflammatory conditions, including obesity and diabetes [5].

Beyond sepsis, 5-LOX plays a role in various inflammatory injuries, such as neuroinflammation and spinal cord injuries, contributing to processes like ferroptosis, a specific form of cell death [6]. Its involvement in tumor-associated inflammation further emphasizes its significance in chronic inflammatory diseases [7]. Although the roles of leukotriene receptors in inflammation are established,



Figure 1: chapter structure

their potential as therapeutic targets remains underexplored, presenting opportunities for intervention [5].

The activation of 5-LOX by exotoxins from Staphylococcus aureus, leading to leukotriene biosynthesis, underlines its critical role in the inflammatory response during bacterial infections [8]. Furthermore, the metabolism of cysteinyl leukotrienes in human eosinophils, particularly in allergic diseases like asthma and aspirin-exacerbated respiratory disease (AERD), highlights the enzyme's broader relevance in inflammatory conditions [9].

The dual functionality of 5-LOX in acute and chronic inflammatory conditions positions it as a vital target for understanding and potentially mitigating the pathophysiology of sepsis and related disorders. Developing effective anti-inflammatory agents that concurrently inhibit both COX-2 and 5-LOX pathways, without the adverse effects associated with traditional NSAIDs, represents a promising research avenue [10]. Consequently, the comprehensive role of 5-LOX in inflammation underscores its importance in both disease progression and potential treatment strategies for sepsis and other inflammatory conditions.

1.2 Importance of Leukotrienes in the Immune Response

Leukotrienes, produced via the 5-LOX pathway, are crucial lipid mediators in immune responses, particularly in orchestrating inflammatory and allergic reactions. These eicosanoids are instrumental in the signaling processes governing leukocyte recruitment, adhesion, and activation. Notably,

leukotriene B4 (LTB4) is recognized for its ability to recruit neutrophils and other immune cells to inflammation sites, thereby amplifying the inflammatory response [1]. This recruitment is facilitated through specific signaling pathways and molecular interactions, highlighting the complexity of leukotriene-mediated immune modulation [8].

Leukotrienes are not only central to acute inflammation but also play significant roles in chronic inflammatory conditions and immune dysfunction, particularly in sepsis survivors. Understanding leukotriene pathways is essential for improving health outcomes in these individuals [2]. Furthermore, leukotrienes influence the tumor microenvironment, impacting tumor growth, metastasis, and responses to immunotherapy [7].

Leukotrienes also modulate leukocyte adhesion, a critical aspect of the immune response mediated by molecules such as L-selectin. This adhesion can be influenced by factors like substrate rigidity, which alters leukocyte behavior and the overall immune response [3]. The therapeutic potential of targeting leukotriene receptors is evident in conditions such as asthma and allergic rhinitis, where receptor antagonists effectively reduce inflammation [9].

The dual functionality of the 5-LOX pathway in synthesizing both pro-inflammatory leukotrienes and anti-inflammatory specialized pro-resolving mediators (SPMs) adds complexity to its viability as a therapeutic target. Precise modulation of this pathway is necessary to selectively enhance therapeutic effects while minimizing adverse outcomes. Recent studies indicate the pathway's involvement in various inflammatory diseases, suggesting that targeted inhibition or activation of specific 5-LOX-derived lipid mediators could lead to more effective treatments for asthma, cardiovascular diseases, and other inflammatory disorders [5, 10, 11, 12, 13]. This complexity reflects broader eicosanoid biology, where advancements in understanding these pathways could significantly impact human health and disease management.

1.3 Structure of the Survey

This survey is structured into several key sections that collectively provide a comprehensive examination of the role of 5-lipoxygenase (5-LOX) in sepsis and inflammation. The survey begins with an **Introduction**, establishing the relevance of 5-LOX to sepsis and inflammation, and highlighting the importance of leukotrienes as inflammatory mediators in the immune response, setting the stage for subsequent discussions.

The **Background** section offers an overview of 5-LOX, detailing its biological function and critical role in leukotriene biosynthesis. This section also explores general mechanisms of inflammation and the immune response, focusing on macrophage involvement.

In **5-LOX and Leukotrienes**, the survey delves into the biochemical pathways of leukotriene synthesis through 5-LOX, describing different types of leukotrienes and their specific roles in inflammatory processes. This section also examines the signaling pathways activated by leukotrienes, their regulation and modulation, and their involvement in disease pathogenesis.

The next section, **Macrophage Activity in Inflammation**, explores how 5-LOX influences macrophage activity, discussing their dual role in promoting and resolving inflammation and how leukotrienes affect these processes.

In **5-LOX in Sepsis**, the survey examines the enzyme's role in sepsis pathophysiology, analyzing how 5-LOX activity can exacerbate or mitigate sepsis outcomes through its effects on the immune response. This section also identifies challenges and knowledge gaps in current sepsis research.

The **Therapeutic Implications** section discusses current and potential therapeutic strategies targeting 5-LOX and leukotrienes in treating sepsis and inflammatory diseases. It reviews existing drugs and their efficacy, emerging research directions, and the role of personalized medicine and diagnostic tools in treating sepsis.

Finally, the **Conclusion** summarizes the key points discussed throughout the paper, emphasizing the significance of 5-LOX in inflammation and sepsis, and the potential for therapeutic interventions targeting this pathway. The survey concludes with a detailed discussion on future research directions, highlighting the need to address critical challenges in the management, epidemiology, and underlying causes of sepsis and septic shock, as identified by a consensus committee of international experts [14, 15].The following sections are organized as shown in Figure 1.

2 Background

2.1 5-LOX Biological Function and Leukotriene Biosynthesis

5-lipoxygenase (5-LOX) is pivotal in arachidonic acid metabolism, converting it into leukotrienes, which are critical lipid mediators in inflammation. This conversion begins with arachidonic acid forming 5-hydroperoxyeicosatetraenoic acid (5-HPETE), which then becomes leukotriene A4 (LTA4). LTA4 is a precursor for leukotriene B4 (LTB4) and cysteinyl leukotrienes (cysLTs), both crucial for modulating immune responses and inflammation [8].

5-LOX's influence extends beyond leukotriene biosynthesis, affecting various metabolic and immune regulatory mechanisms. LTB4 enhances inflammatory conditions like rheumatoid arthritis by promoting pain and bone degradation, while leukotrienes contribute to airway obstruction and inflammation in asthma [9]. The enzyme is also essential for producing leukocyte-derived inflammatory eicosanoids, impacting the pathogenesis of inflammatory bowel diseases (IBDs) [9].

In acute inflammation, particularly sepsis, 5-LOX is crucial for systemic inflammation and organ dysfunction, influencing immune cell recruitment and activation, especially neutrophils, which are vital for host defense but can be harmful if dysregulated [3]. The dual role of 5-LOX in pro-inflammatory and anti-inflammatory processes complicates the development of specific inhibitors [8].

5-LOX-mediated leukotriene production is also significant in metabolic regulation, especially in obesity-related disorders where inflammatory mediators disrupt metabolic homeostasis. The enzyme's interactions with leukotriene receptors highlight its complex contributions to inflammation and immune regulation, influencing both pro-inflammatory and specialized pro-resolving mediators, complicating therapeutic strategies for diseases like asthma and cancer [5, 8, 16, 12, 17]. The intricate role of 5-LOX in leukotriene biosynthesis underscores its significance in both physiological and pathological contexts, presenting opportunities and challenges for therapeutic interventions.

2.2 General Mechanisms of Inflammation

Inflammation is a complex biological response to harmful stimuli, such as pathogens, damaged cells, and irritants, aiming to eliminate injurious agents and facilitate tissue repair. It involves immune cell recruitment, pro-inflammatory cytokine release, and activation of complex signaling pathways [11]. Chronic inflammation can lead to various diseases, necessitating a deep understanding of its mechanisms.

Leukotrienes, synthesized via the 5-LOX pathway, are key mediators in inflammation, influencing leukocyte recruitment and activation in conditions like asthma. Recent studies have highlighted the complexity of leukotriene production and their interactions with G protein-coupled receptors (GPCRs), underscoring their potential as therapeutic targets for managing inflammatory conditions and infections. The activation of 5-LOX by pathogenic factors, such as Staphylococcus aureus exotoxins, underscores its role in neutrophil responses during infection [5, 8, 12, 13, 17]. This complexity complicates understanding their roles in diseases like asthma and cardiovascular diseases, particularly the cysteinyl leukotrienes (cysLTs) signaling pathways in eosinophil biology and allergic inflammation.

Macrophages are central to the inflammatory response due to their ability to polarize into different phenotypes, affecting lipid mediator biosynthesis and intracellular calcium mobilization [11]. This plasticity allows macrophages to promote or resolve inflammation based on the context. Understanding macrophage dynamics and their interactions with leukotrienes is crucial for developing targeted therapies to modulate inflammation.

Pro-inflammatory cytokine dysregulation can lead to severe outcomes, such as cytokine storms, causing organ damage and multi-organ failure [2]. This highlights the necessity for precise modulation of inflammatory responses to prevent adverse effects. Despite advances in inflammation research, challenges remain in elucidating specific protein roles, like TIRAP, in modulating inflammatory responses in acute and chronic conditions.

Advancements in mass spectrometry have improved the identification of eicosanoid entities, enhancing our understanding of lipid mediator dynamics in inflammation [18]. However, the variability in

inflammation types and patient-specific responses presents challenges for model-based therapeutic approaches, emphasizing the need for innovative strategies to control inflammation [7].

Inflammation mechanisms involve a complex interplay among immune cells, cytokines, and signaling pathways, with critical roles played by molecules like TIRAP, which regulates immune responses and maintains tissue homeostasis. Understanding these dynamics is essential for effectively managing acute inflammatory responses, such as those triggered by infections, and can inform therapeutic strategies for sepsis and other inflammatory disorders [19, 20, 21, 22]. A deeper understanding of these mechanisms is crucial for developing effective interventions that mitigate chronic inflammation's detrimental effects and improve patient outcomes.

2.3 Macrophages in the Immune Response

Macrophages are crucial in the immune response, acting as regulatory hubs that initiate, perpetuate, and resolve inflammation [23]. These versatile immune cells, originating from monocytes, exhibit remarkable plasticity, enabling them to adopt various activation states in response to environmental cues [24]. This plasticity is vital for their roles in numerous physiological and pathological processes, including chronic inflammation and cancer.

In inflammation, macrophages are involved in both sterile and non-sterile processes, playing critical roles in conditions like rheumatoid arthritis and allergic asthma by producing pro-inflammatory cytokines and chemokines [25]. Their interactions with other immune cells and modulation of leukotriene signaling further underscore their importance in the inflammatory response [16].

Macrophages also contribute to tissue repair and homeostasis, resolving inflammation and restoring tissue integrity through the phagocytosis of apoptotic cells and debris. This function is essential for preventing chronic inflammation and associated tissue damage. However, dysregulated macrophage activity can lead to pathological conditions, highlighting the need for a deeper understanding of their molecular interactions and regulatory mechanisms [26].

Despite their central role in the immune response, challenges remain in fully elucidating the molecular mechanisms governing macrophage function and plasticity. The limited understanding of these processes, particularly in conditions like lymphedema, where effective therapeutic options are lacking, underscores the need for further research [27]. Advances in macrophage biology may inform the development of targeted therapies that modulate macrophage activity to treat inflammatory diseases and improve patient outcomes.

In examining the biochemical pathways involved in leukotriene synthesis, it is essential to understand the hierarchical structure that governs the activity of 5-lipoxygenase (5-LOX) and its associated pathways. This understanding is crucial as it provides insights into the various types and roles of leukotrienes, their signaling pathways, and the regulatory mechanisms that modulate these processes. Figure 2 illustrates this hierarchical structure, detailing not only the synthesis of leukotrienes but also their implications in disease pathogenesis. By analyzing this figure, we can better appreciate the complexity of leukotriene signaling and its relevance to various pathophysiological conditions.

3 5-LOX and Leukotrienes

3.1 Biochemical Pathway of Leukotriene Synthesis

Leukotriene synthesis, initiated by 5-lipoxygenase (5-LOX), is crucial in inflammatory processes. This pathway begins with 5-LOX, aided by the 5-lipoxygenase-activating protein (FLAP), converting arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE), which is then dehydrated to form leukotriene A4 (LTA4) [8]. LTA4 serves as a pivotal intermediate, either hydrolyzed by leukotriene A4 hydrolase (LTA4H) to produce leukotriene B4 (LTB4), a strong pro-inflammatory agent [1], or conjugated with glutathione via leukotriene C4 synthase (LTC4S) to yield leukotriene C4 (LTC4), subsequently converted to LTD4 and LTE4 [7].

Regulating this pathway is essential for balancing inflammatory responses. Modulating the 5-LOX/LTB4 axis has therapeutic potential in reducing inflammation, as seen in cerebral ischemia [28, 12]. The complex roles of cysteinyl leukotrienes (cysLTs) in signaling through intracrine, paracrine, and autocrine pathways further highlight the intricacies of leukotriene regulation [5].



Figure 2: This figure illustrates the hierarchical structure of 5-LOX and leukotriene pathways, detailing the biochemical synthesis, types and roles of leukotrienes, signaling pathways, regulation and modulation, and their implications in disease pathogenesis.

Understanding the LTB4-BLT1 and cysLT receptor pathways is critical for developing therapies targeting leukotriene-mediated inflammation, particularly in asthma [5, 15]. The 5-LOX pathway's intricate network presents both challenges and opportunities for therapeutic interventions, necessitating ongoing research into its molecular complexities.

3.2 Types of Leukotrienes and Their Roles

Leukotrienes, derived from arachidonic acid via the 5-LOX pathway, are key lipid mediators in inflammatory and immune responses, especially in asthma and allergies. They operate at low concentrations, exerting diverse effects based on target cells. Categorized into leukotriene B4 (LTB4) and cysteinyl leukotrienes (cys-LTs), including LTC4, LTD4, and LTE4, they highlight 5-LOX's dual role in producing both pro-inflammatory and anti-inflammatory mediators [5, 12].

LTB4 is a potent pro-inflammatory mediator, crucial for neutrophil recruitment and activation, influencing T cell responses and cell adhesion, essential in conditions like asthma and rheumatoid arthritis [8, 1]. Cysteinyl leukotrienes (cysLTs) contribute to bronchoconstriction and increased vascular permeability, exacerbating asthma and allergic reactions through specific receptors like CysLT1 and CysLT2 [7, 9].

Leukotriene interactions with cell adhesion molecules, such as L-selectin, further modulate inflammation [29]. Understanding these roles is vital for developing therapies targeting chronic inflammatory and allergic diseases, optimizing strategies to harness their regenerative potential [21, 30].

3.3 Leukotriene Signaling Pathways

Leukotrienes, synthesized via the 5-LOX pathway, are pivotal in activating signaling pathways that regulate inflammation and immunity. This includes producing pro-inflammatory leukotrienes like LTB4 and specialized pro-resolving mediators. Staphylococcal exotoxins can specifically trigger 5-LOX activation, suggesting its therapeutic potential beyond asthma [8]. Leukotrienes primarily exert effects through G protein-coupled receptors, including BLT1/2 for LTB4 and CysLT1/2 for cysLTs.

Receptor binding activates signaling cascades, leading to transcription factor activation and pro-inflammatory gene expression, with proteins like TIRAP amplifying responses [20]. This underscores leukotriene signaling's impact on immune regulation, where dysregulation can lead to chronic inflammation in diseases like obesity and diabetes [20, 31].

Understanding leukotriene signaling mechanisms is crucial for developing therapies targeting these pathways, reducing inflammation, and improving outcomes in inflammatory diseases [5, 27].

3.4 Regulation and Modulation of Leukotriene Synthesis

Regulating leukotriene synthesis is crucial for balancing inflammatory responses. The 5-LOX pathway, converting arachidonic acid into leukotrienes, involves complex regulation by soluble and membrane-bound enzymes. This regulation is essential for immune homeostasis and therapeutic targeting, given leukotrienes' roles in inflammation [5, 8].

FLAP, crucial for 5-LOX activation, modulates leukotriene biosynthesis by facilitating 5-LOX translocation to the nuclear membrane [8]. Arachidonic acid availability, regulated by phospholipase A2, is a rate-limiting step in leukotriene production. Pharmacological agents, like flavonoid derivatives, selectively inhibit COX-2 and 5-LOX, reducing inflammation without typical NSAID side effects [10].

5-LOX expression is transcriptionally regulated by cytokines and growth factors, while post-translational modifications, such as phosphorylation, modulate its activity [12]. Understanding these regulatory mechanisms is vital for developing therapies targeting leukotriene synthesis, particularly for inflammatory and allergic diseases [5, 13].

3.5 Leukotrienes in Disease Pathogenesis

Leukotrienes, via the 5-LOX pathway, are crucial in the pathogenesis of inflammatory diseases. Eicosanoids like LTB4 and cysLTs play significant roles in conditions like asthma, where LTB4 acts as a potent neutrophil chemoattractant and cysLTs regulate eosinophil activity, enhancing inflammation [5, 4].

LTB4 is pivotal in rheumatoid arthritis, promoting neutrophil recruitment and activation, contributing to joint damage [32]. Cysteinyl leukotrienes are integral to asthma, inducing bronchoconstriction and mucus secretion, exacerbating symptoms [33].

In sepsis, leukotrienes contribute to the dysregulated immune response, influencing disease progression [19]. The role of exotoxins in 5-LOX activation during infections opens avenues for novel therapies [8].

Leukotrienes also have implications in neuroinflammatory conditions, where modulation could offer therapeutic benefits, as seen with inhibitors like edaravone [6]. Advances in understanding leukotriene receptor dynamics could facilitate novel anti-leukotriene drug development, providing new therapeutic avenues for inflammatory diseases [1].

4 Macrophage Activity in Inflammation

Macrophages are pivotal in immune response modulation and inflammation outcomes, influenced by biochemical signals and environmental factors. Understanding macrophage behavior in inflammation is critical, particularly the role of 5-lipoxygenase (5-LOX) in macrophage polarization, which shapes their functional states and contributions to inflammation.

4.1 Influence of 5-LOX on Macrophage Polarization

5-lipoxygenase (5-LOX) is crucial in macrophage polarization, facilitating the transition to pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes. It modulates leukotriene production, especially leukotriene B4 (LTB4), a key inflammatory mediator [24]. Exotoxins like phenol-soluble modulins activate 5-LOX in neutrophils, enhancing leukotriene synthesis and affecting macrophage activity [8]. Mathematical models reveal 5-LOX's role in macrophage activation, considering physical and biochemical influences [29]. Macrophage adaptability, influenced by 5-LOX, is evident in the regulation of cysteinyl leukotriene metabolism and microbial interactions [9, 11]. The dual role of 5-LOX in producing both pro-inflammatory and anti-inflammatory mediators highlights its complexity in macrophage polarization [24, 12]. Understanding these dynamics is crucial for developing strategies to harness macrophage plasticity in treating inflammatory diseases.

4.2 Macrophage Activity in Tissue Repair and Fibrosis

Macrophages regulate tissue repair and fibrosis, switching between pro-inflammatory (M1) and anti-inflammatory (M2) states to manage cellular and molecular events necessary for healing [24]. Their plasticity is vital for tissue regeneration, as shown in models where modulating macrophage plasticity improved repair outcomes [30]. In fibrosis, macrophages influence extracellular matrix modulation and fibrogenesis, as seen in pulmonary fibrosis where leukotrienes from senescent fibroblasts promote profibrotic signaling [15]. Macrophages' dual role in repair and fibrosis makes them potential targets for regenerative therapies, allowing modulation of functions to enhance healing and reduce scarring [23, 24, 30, 25]. Further research into macrophage function and plasticity is necessary to improve tissue regeneration and mitigate fibrosis.

4.3 Macrophage Dynamics in Chronic Inflammatory Diseases

Macrophages play dynamic roles in chronic inflammatory diseases, transitioning between pro-inflammatory (M1) and anti-inflammatory (M2) states to adapt to microenvironmental cues [24]. In conditions like rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease, macrophages sustain inflammation through cytokine and chemokine production, exacerbating tissue damage. Standardizing macrophage characterization is challenging, complicating comparisons across studies [30]. Species-specific differences also hinder translating animal model findings to humans. Despite advances, questions remain about macrophage plasticity mechanisms and their interactions with other immune cells in chronic inflammation [24]. Understanding these interactions is crucial for developing therapies that modulate macrophage activity to reduce chronic inflammation. Research focuses on molecular pathways regulating macrophage function, highlighting epigenetic factors, transcription networks, and environmental cues [24, 30]. Enhancing this understanding could lead to novel regenerative medicine strategies, leveraging macrophage plasticity to improve patient outcomes by mitigating inflammation and promoting tissue repair.

5 5-LOX in Sepsis

5.1 Pathophysiology of Sepsis

Sepsis arises from the body's dysregulated response to infection, characterized by a disbalance between pro-inflammatory and anti-inflammatory mediators, leading to systemic inflammation and potential organ failure [34, 3]. This imbalance often manifests as systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction, complicating management strategies. The heterogeneity of sepsis, with its variable inflammatory responses among individuals, underscores the need for robust immune-related signatures to enhance diagnostics and treatment efficacy [35].

Mathematical models have elucidated the dynamics of acute inflammation in sepsis, emphasizing the delicate balance between pro-inflammatory mediators and pathogen virulence necessary for an effective immune response [19]. Understanding the impact of inflammation on the autonomic control system is crucial for recovery, as inflammation can lead to systemic complications like sepsis, especially in intensive care settings [21, 36]. Despite advances, the lack of effective diagnostic biomarkers remains a barrier to timely diagnosis, highlighting the urgent need for improved tools and strategies.

Sepsis pathophysiology involves complex interactions among immune, metabolic, and autonomic factors, characterized by hyperactivity of innate immune responses, particularly TH17-like pathways, and hypoactivity of adaptive immunity [37]. A multifaceted research approach integrating computational modeling and network-based analyses is required to refine predictive models and guide therapeutic interventions, aiming to mitigate sepsis's detrimental effects and improve patient outcomes [36].

5.2 Role of 5-LOX in Sepsis Progression

5-lipoxygenase (5-LOX) is integral to sepsis progression through its role in leukotriene biosynthesis, which are crucial mediators of inflammation. Dysregulation of the 5-LOX pathway can exacerbate inflammatory responses, contributing to sepsis pathology [28]. The 5-LOX/leukotriene B4 (LTB4) axis modulates the inflammatory milieu, influencing both innate and adaptive immune responses [37].

Strategies to restore immune homeostasis by modulating pro- and anti-inflammatory mediators are proposed to mitigate sepsis effects, with the 5-LOX pathway being a viable target for therapeutic interventions [38]. Dual inhibition of COX-2 and 5-LOX may provide effective anti-inflammatory effects with reduced side effects, beneficial for managing sepsis's inflammatory cascade [10].

Mathematical models have identified critical parameters influencing sepsis progression, emphasizing leukotrienes' significant impact on immune response dynamics [39, 40]. The therapeutic potential of 5-LOX inhibitors extends beyond sepsis, as demonstrated by rosemary essential oil's inhibitory effects on 5-LOX [41]. Advanced computational methods, like deep reinforcement learning, could facilitate the development of adaptive multi-cytokine therapies tailored to real-time patient data [35].

5-LOX's role in sepsis involves intricate interactions between leukotriene-mediated signaling and immune system dynamics, necessitating targeted interventions to modulate the inflammatory response. Sepsis affects over 30 million individuals globally each year and remains a leading cause of mortality in critical care, highlighting the importance of advancing our understanding of its pathogenesis and host response dynamics [14, 2, 36].

5.3 Leukotrienes and Immune Dysregulation

Leukotrienes are central to the immune dysregulation in sepsis, characterized by an imbalanced immune response leading to systemic inflammation and organ dysfunction. This dysregulation involves overactivation of innate immune responses and suppression of adaptive immunity, as shown by microarray analyses of septic patients' blood [37]. LTB4, known for its potent pro-inflammatory effects, recruits and activates neutrophils at infection sites, though its interactions with other cytokines require further investigation [32].

Recent efforts to classify sepsis into distinct sub-phenotypes highlight the complexity of immune dysregulation, providing insights into the heterogeneity of immune responses among patients [42]. Such classifications can inform therapeutic interventions targeting specific leukotriene-mediated pathways, potentially improving patient outcomes.

Advancements in diagnostic approaches emphasize the need for robust immune-related signatures for sepsis, demonstrating high diagnostic accuracy across platforms and outperforming existing biomarkers [43]. Integrating these diagnostic tools with an understanding of leukotriene-mediated immune dysregulation could enhance sepsis management strategies, enabling targeted modulation of leukotriene pathways to restore immune balance and mitigate adverse effects.

5.4 Challenges and Knowledge Gaps in Sepsis Research

Sepsis research faces numerous challenges and knowledge gaps that hinder the development of effective diagnostic and therapeutic strategies. The inherent complexity and dynamic nature of sepsis complicate traditional research methods [36]. Multifaceted interactions within the immune network are difficult to accurately represent in current models, complicating outcome predictions and treatment optimization [40].

Diagnosing sepsis remains challenging due to its non-specific clinical manifestations, often resulting in delayed interventions. The rise of antibiotic-resistant infections further complicates this issue, diminishing the efficacy of conventional therapies [31]. Existing diagnostic methods, including

clinical scores and machine learning algorithms, inadequately capture the temporal changes leading to sepsis onset, making it difficult to predict the condition within the critical 6-hour window before clinical symptoms appear.

Significant knowledge gaps persist regarding the long-term effects of sepsis, particularly concerning survivors' quality of life and effective post-discharge care [44]. The evolving definition of sepsis has exposed gaps in understanding the condition in pediatric populations and economically disadvantaged regions, as well as in the validation of screening tools across diverse populations [45].

The complexity of leukotriene biosynthesis and their multifaceted roles in various pathologies present challenges in effectively targeting these pathways [5]. Current therapeutic strategies have not successfully targeted both COX-2 and 5-LOX pathways simultaneously, resulting in insufficient outcomes and increased side effects [46]. Gaps remain in understanding the full pathophysiological mechanisms of sepsis, particularly regarding cellular dysfunction and immune response regulation [2]. This lack of clarity extends to potential therapeutic modulation of TH17 and Treg responses in conditions like acute respiratory distress syndrome (ARDS) [3].

Additionally, unanswered questions persist regarding environmental factors influencing eosinophil metabolism and their therapeutic targeting [9]. The limitations of current benchmarks in capturing novel eicosanoids, particularly those with unique fragmentation patterns, further complicate understanding lipid mediator dynamics in sepsis [18].

Addressing the multifaceted challenges associated with sepsis and inflammatory diseases requires a comprehensive multidisciplinary approach. This should integrate advanced computational models, like agent-based simulations and in silico modeling, alongside innovative diagnostic tools such as directed non-targeted mass spectrometry for eicosanoid discovery, and targeted therapeutic strategies utilizing adaptive, personalized multi-cytokine therapies. Such integration will enhance our understanding of complex biological interactions and improve clinical outcomes by tailoring interventions to individual patient profiles, ultimately addressing the intricate dynamics of host-pathogen interactions and immune responses [35, 36, 18, 23, 26]. Enhancing our understanding of sepsis as a complex, systemic condition is crucial for improving patient outcomes and reducing the global burden of this life-threatening syndrome.

6 Therapeutic Implications

6.1 Therapeutic Targeting of Macrophage-Leukotriene Interactions

Macrophage-leukotriene interactions represent a promising target for treating inflammatory diseases, given macrophages' dual role in driving and resolving inflammation [25]. Their phenotypic plasticity, influenced by various microenvironmental cues, allows them to either promote or mitigate inflammation [24]. This adaptability suggests potential therapeutic interventions aimed at modulating macrophage behavior to achieve better clinical outcomes.

Strategies include designing biomaterials that influence macrophage activity or delivering exogenous cells to inflammation sites [30]. Targeting macrophage-leukotriene interactions could finely adjust the inflammatory response, potentially improving therapeutic outcomes. Dual inhibition of COX-2 and 5-LOX pathways may reduce inflammation while minimizing side effects [46].

Advanced computational methods, like the RNN-BO algorithm, offer innovative strategies for optimizing sepsis treatment plans by predicting optimal control strategies [40]. These methods enable personalized treatment based on real-time data, enhancing outcomes compared to static therapies [35]. Integrating computational approaches with macrophage-leukotriene interaction insights can refine therapeutic precision.

The contextualized interactome, enriched in immune response and apoptosis pathways, provides insights into the complex protein-protein interactions governing macrophage function and leukotriene signaling [26]. This knowledge is critical for identifying novel therapeutic targets within the macrophage-leukotriene axis.

Investigating macrophage-leukotriene interactions as therapeutic targets offers significant potential for innovative treatments in inflammatory diseases, including asthma, allergic rhinitis, cardiovascular diseases, neurodegenerative disorders, and certain cancers [5, 13]. By leveraging macrophage

plasticity and advanced computational tools, more effective and personalized therapeutic strategies can be developed to address inflammation complexities.

6.2 Challenges in Sepsis Management

Sepsis management is fraught with challenges due to its complexity and the multifaceted inflammatory response. A major challenge is the limited recognition of leukotriene receptors' roles across diseases, with therapeutic efforts historically focused elsewhere [13]. This oversight impedes the development of targeted therapies that could effectively modulate inflammation.

Clinical studies often lack comprehensive data, leading to uncertainties in practice [14]. This ambiguity complicates standardized treatment protocol formulation, underscoring the need for robust research to guide clinical decisions. The complexity of macrophage biology and challenges in translating research findings into clinical applications further hinder effective strategy development [24].

Advanced computational approaches, such as the RNN-BO algorithm, have shown promise in predicting optimal control strategies for sepsis treatment, outperforming traditional methods in speed and accuracy [40]. However, these methods depend heavily on high-quality data, and issues like class imbalance in datasets can significantly impact model performance [34]. This reliance on data quality highlights the importance of developing comprehensive and balanced datasets to enhance computational model efficacy in sepsis management.

Sepsis management is complicated by several factors: limited understanding of leukotrienes' roles in inflammation, significant gaps in current research methodologies, and challenges in translating scientific insights into clinical practice. Addressing these issues requires a multidisciplinary approach that integrates complex systems science with biological data to improve understanding and treatment of this life-threatening condition [45, 14, 2, 36]. Enhancing understanding of sepsis pathophysiology, improving data quality for computational models, and exploring underutilized pathways like leukotrienes are critical for overcoming these challenges.

6.3 Emerging Research and Therapeutic Strategies

Advancements in sepsis and inflammation therapy underscore the importance of targeting specific molecular pathways to address these conditions' complexities. A notable direction is developing therapies targeting the 5-LOX/LTB4 pathway, crucial in inflammatory responses. This approach is particularly relevant in asthma, where leukotriene pathways are critical in pathogenesis, suggesting that targeting these pathways could enhance therapeutic strategies [9].

Emerging research demonstrates the efficacy of multi-subset approaches for early sepsis prediction, showing high accuracy in distinguishing sepsis from septic shock. Machine learning algorithms leveraging temporal data trends can predict sepsis onset up to six hours before clinical suspicion, significantly improving early detection. Advanced meta-ensemble models have achieved superior predictive accuracy, with an AUC-ROC score of 0.96, enhancing the likelihood of timely treatment and better patient outcomes [43, 36, 34, 47, 42]. Integrating pharmacokinetic and pharmacodynamic models can further enhance predictive capabilities, simulating therapeutic outcomes realistically. The proposed model-free control approach effectively manages inflammatory responses, achieving stabilization in simulated patients and demonstrating robustness against parameter variations.

Exploring leukotriene signaling as a therapeutic target in pulmonary fibrosis represents another promising avenue. Understanding the temporal dynamics of the senescence-associated secretory phenotype (SASP) and its interaction with leukotriene pathways is crucial for developing targeted interventions to mitigate pulmonary fibrosis, as leukotrienes released by senescent cells exacerbate inflammation and tissue remodeling [12, 15]. Additionally, modulating macrophage behavior through innovative biomaterials and standardizing macrophage characterization protocols are critical areas for future research, aiming to leverage macrophage plasticity for improved outcomes.

Future research should focus on optimizing the chemical structures of leukotriene receptor antagonists to enhance their efficacy and selectivity in managing chronic inflammatory diseases. Given leukotrienes' critical role in immune responses and inflammation, insights from recent studies on leukotriene receptors can guide the development of more effective antagonists targeting these pathways, ultimately improving treatment outcomes for conditions like asthma and allergic rhinitis

[13, 12]. Integrating additional parameters, such as flow conditions and ligand density, into cell adhesion models could provide deeper insights into the inflammatory process and aid in validating therapeutic strategies against experimental data.

Moreover, exploring the allosteric modulation of 5-LOX and developing inhibitors that preferentially enhance specialized pro-resolving mediators (SPM) production represents an innovative area for future work [8]. Utilizing urolithins offers a novel mechanism for reducing inflammation without the side effects associated with traditional drugs.

Emerging research and therapeutic strategies in sepsis and inflammation emphasize the need for targeted interventions addressing underlying molecular mechanisms. By focusing on specific biological pathways and utilizing advanced modeling techniques, such as deep reinforcement learning and in silico approaches, researchers can develop more effective and personalized therapeutic strategies. These approaches, particularly for complex conditions like sepsis, have the potential to significantly enhance patient outcomes by adapting treatment protocols based on individual patient parameters and real-time feedback, thereby addressing the intricate dynamics of immune responses and improving intervention efficacy [35, 40, 36, 30, 23]. Future research should continue to explore personalized treatment approaches, improved diagnostic tools, and a deeper understanding of the biological underpinnings of sepsis.

6.4 Personalized Medicine and Diagnostic Tools

Integrating personalized medicine and advanced diagnostic tools into sepsis treatment represents a transformative approach to managing this complex condition. Personalized medicine focuses on tailoring medical treatment to individual patient characteristics, which is particularly beneficial in sepsis due to its heterogeneity and variability in patient responses. This approach requires a comprehensive understanding of underlying pathophysiological mechanisms, including the dual role of 5-lipoxygenase (5-LOX) in pro-inflammatory and anti-inflammatory processes [12]. Recognizing 5-LOX's dual roles is crucial for developing therapeutic strategies that effectively modulate inflammation without exacerbating the condition.

Recent research highlights the importance of longitudinal biological data collection in informing treatment strategies through complex systems science [36]. This data-driven approach enables the identification of specific biomarkers and immune-related signatures that guide personalized therapeutic interventions, enhancing sepsis management precision by allowing clinicians to predict disease progression and tailor treatments accordingly.

Diagnostic tools are pivotal for early sepsis detection and management, providing critical insights into patients' immune status and inflammatory response dynamics. Identifying leukotriene receptors BLT1 and BLT2 as therapeutic targets opens new intervention avenues, with evidence supporting their roles in managing inflammatory diseases [13]. Targeting these receptors could lead to more effective treatments addressing specific inflammatory pathways involved in sepsis.

Advancements in personalized medicine and diagnostic tools hold significant promise for improving sepsis treatment outcomes. By harnessing precision medicine advancements, such as adaptive, personalized multi-cytokine therapy, healthcare providers can create tailored treatment plans for sepsis, a life-threatening condition affecting millions globally with high mortality rates. This innovative approach utilizes deep reinforcement learning and simulation models to optimize treatment strategies based on individual patient responses, thereby improving patient outcomes, enhancing care quality, and potentially reducing the economic burden associated with sepsis management [35, 30, 38, 14, 2].

6.5 Role of Macrophages in Therapeutic Interventions

Macrophages play a pivotal role in therapeutic interventions due to their central function in modulating inflammatory responses and maintaining tissue homeostasis. Their ability to adopt various phenotypes, including pro-inflammatory M1 and anti-inflammatory M2 states, enables them to participate in both initiating and resolving inflammation, making them attractive targets for therapeutic strategies [24]. Harnessing macrophage plasticity can lead to interventions that either promote anti-inflammatory functions or inhibit pro-inflammatory activities, depending on therapeutic needs.

Targeting macrophage polarization offers a promising strategy for treating chronic inflammatory diseases, where the balance between M1 and M2 phenotypes is often disrupted. Modulating macrophage

polarization can shift the immune response towards a more anti-inflammatory state, alleviating chronic inflammation and promoting tissue repair [25]. This approach is particularly relevant in conditions like rheumatoid arthritis and atherosclerosis, where macrophages significantly contribute to disease progression.

Developing biomaterials designed to influence macrophage behavior represents an innovative therapeutic intervention. These materials can deliver specific signals modulating macrophage activity, enhancing their therapeutic potential [30]. Additionally, delivering exogenous macrophages with tailored phenotypes to inflammation sites provides a direct means of modulating the immune response and promoting tissue regeneration.

Exploring macrophage-leukotriene interactions as therapeutic targets highlights the potential for developing interventions that specifically target the signaling pathways involved in macrophage activation and function. Understanding the complex network of interactions between macrophages and leukotrienes can identify novel therapeutic intervention targets that effectively modulate inflammatory responses [26].

The pivotal role of macrophages in therapeutic interventions underscores the need for a comprehensive understanding of their diverse biology, including plasticity, activation pathways, and regulatory mechanisms governing their functions. This knowledge is crucial for developing effective macrophage-based therapies, particularly in regenerative medicine, where leveraging their ability to shift phenotypes can significantly influence tissue repair and resolution of inflammatory responses in various pathological conditions [23, 24, 30]. By capitalizing on macrophage plasticity and versatility, targeted therapies can be developed to address underlying inflammation mechanisms and promote tissue healing, offering new hope for patients with chronic inflammatory diseases.

7 Conclusion

7.1 Future Directions and Challenges

Advancing research on 5-lipoxygenase (5-LOX) and leukotriene pathways, particularly within the realm of sepsis and inflammation, necessitates a focus on developing targeted therapeutic agents that enhance adaptive immune responses. Emphasis should be placed on exploring BLT1 antagonists and understanding the dual roles of BLT2 to potentially improve treatment outcomes in conditions like asthma. Integrating advanced computational models with clinical datasets will be pivotal in refining predictive strategies for sepsis management, enhancing model transparency, and incorporating cardiovascular components to improve accuracy and applicability.

Further exploration of macrophage plasticity and polarization is essential to uncover the molecular pathways influencing macrophage behavior, which could lead to innovative therapies that utilize macrophage adaptability for better disease management. Enhancing in silico models in macrophage research will aid in data integration and broaden therapeutic applications. Investigating the metabolic pathways of natural compounds, such as urolithins, and their potential synergistic effects across different metabotypes could reveal new therapeutic avenues.

The contextualization and robustness of protein-protein interaction networks should be improved by incorporating supplementary data sources, thereby advancing research in this area. Personalized medicine, especially lipid profile assessments, should be prioritized to tailor therapeutic strategies in complex diseases like cancer, where leukotrienes play a significant role. Elucidating the molecular pharmacology of cysteinyl leukotriene receptors and exploring dual receptor antagonists is crucial for developing more effective treatments. Addressing these challenges requires a multidisciplinary approach, integrating insights from molecular biology, computational modeling, and clinical research, to foster the development of personalized and effective therapeutic interventions.

References

[1] Na Wang, Xinheng He, Jing Zhao, Hualiang Jiang, Xi Cheng, Yu Xia, H Eric Xu, and Yuanzheng He. Structural basis of leukotriene b4 receptor 1 activation. *Nature communications*, 13(1):1156, 2022.

[2] Min Huang, Shaoli Cai, and Jingqian Su. The pathogenesis of sepsis and potential therapeutic targets. *International journal of molecular sciences*, 20(21):5376, 2019.

[3] Wan-Chung Hu. Acute respiratory distress syndrome is a th17-like and treg immune disease, 2013.

[4] Glaucia A Thompson-Souza, Isabella Gropillo, and Josiane S Neves. Cysteinyl leukotrienes in eosinophil biology: functional roles and therapeutic perspectives in eosinophilic disorders. *Frontiers in medicine*, 4:106, 2017.

[5] Jesper Z Haeggström et al. Leukotriene biosynthetic enzymes as therapeutic targets. *The Journal of clinical investigation*, 128(7):2680–2690, 2018.

[6] Yilin Pang, Xinjie Liu, Xu Wang, Xuelian Shi, Lei Ma, Yan Zhang, Tiangang Zhou, Chenxi Zhao, Xu Zhang, Baoyou Fan, et al. Edaravone modulates neuronal gpx4/acsl4/5-lox to promote recovery after spinal cord injury. *Frontiers in Cell and Developmental Biology*, 10:849854, 2022.

[7] Erminia Mariani, Gina Lisignoli, Rosa Maria Borzì, and Lia Pulsatelli. Biomaterials: foreign bodies or tuners for the immune response? *International journal of molecular sciences*, 20(3):636, 2019.

[8] Erik Romp, Vandana Arakandy, Jana Fischer, Christiane Wolz, Anke Siegmund, Bettina Löffler, Lorena Tuchscherr, Oliver Werz, and Ulrike Garscha. Exotoxins from staphylococcus aureus activate 5-lipoxygenase and induce leukotriene biosynthesis. *Cellular and Molecular Life Sciences*, 77:3841–3858, 2020.

[9] Jun Miyata, Koichi Fukunaga, Yusuke Kawashima, Osamu Ohara, and Makoto Arita. Cysteinyl leukotriene metabolism of human eosinophils in allergic disease. *Allergology International*, 69(1):28–34, 2020.

[10] Muhd Hanis Md Idris, Siti Norhidayu Mohd Amin, Siti Norhidayah Mohd Amin, Nyotia Nyokat, Heng Yen Khong, Manikandan Selvaraj, Zainul Amiruddin Zakaria, Zurina Shaameri, Ahmad Sazali Hamzah, Lay Kek Teh, et al. Flavonoids as dual inhibitors of cyclooxygenase-2 (cox-2) and 5-lipoxygenase (5-lox): molecular docking and in vitro studies. *Beni-Suef University Journal of Basic and Applied Sciences*, 11(1):117, 2022.

[11] Oliver Werz, Jana Gerstmeier, Stephania Libreros, Xavier De la Rosa, Markus Werner, Paul C Norris, Nan Chiang, and Charles N Serhan. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. *Nature communications*, 9(1):59, 2018.

[12] Nathaniel C Gilbert, Marcia E Newcomer, and Oliver Werz. Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: the battle between pro-and anti-inflammatory lipid mediators. *Biochemical pharmacology*, 193:114759, 2021.

[13] Takehiko Yokomizo, Motonao Nakamura, Takao Shimizu, et al. Leukotriene receptors as potential therapeutic targets. *The Journal of clinical investigation*, 128(7):2691–2701, 2018.

[14] Craig M Coopersmith, Daniel De Backer, Clifford S Deutschman, Ricard Ferrer, Ishaq Lat, Flavia R Machado, Greg S Martin, Ignacio Martin-Loeches, Mark E Nunnally, Massimo Antonelli, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. *Intensive care medicine*, 44:1400–1426, 2018.

[15] Christopher D Wiley, Alexis N Brumwell, Sonnet S Davis, Julia R Jackson, Alexis Valdovinos, Cheresa Calhoun, Fatouma Alimirah, Carlos A Castellanos, Richard Ruan, Ying Wei, et al. Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis. *JCI insight*, 4(24):e130056, 2019.

[16] Wen Tian, Xinguo Jiang, Dongeon Kim, Torrey Guan, Mark R Nicolls, and Stanley G Rockson. Leukotrienes in tumor-associated inflammation. *Frontiers in pharmacology*, 11:1289, 2020.

[17] Erwin W Gelfand. Importance of the leukotriene b4-blt1 and ltb4-blt2 pathways in asthma. In *Seminars in immunology*, volume 33, pages 44–51. Elsevier, 2017.

[18] Jeramie D. Watrous, Teemu Niiranen, Kim A. Lagerborg, Mir Henglin, Yong-Jian Xu, Sonia Sharma, Ramachandran S. Vasan, Martin G. Larson, Aaron Armando, Oswald Quehenberger, Edward A. Dennis, Susan Cheng, and Mohit Jain. Directed non-targeted mass spectrometry and chemical networking for discovery of eicosanoids, 2018.

[19] Rukmini Kumar, Gilles Clermont, Yoram Vodovotz, and Carson Chow. Dynamics of acute inflammation, 2004.

[20] Sajjan Rajpoot, Kishore K Wary, Rachel Ibbott, Dongfang Liu, Uzma Saqib, Teresa LM Thurston, and Mirza S Baig. Tirap in the mechanism of inflammation. *Frontiers in Immunology*, 12:697588, 2021.

[21] Atanaska Dobreva, Renee Brady, Kamila Larripa, Charles Puelz, Jesper Mehlsen, and Mette S. Olufsen. A physiological model of the inflammatory-thermal-pain-cardiovascular interactions during a pathogen challenge, 2019.

[22] Gökhan S Hotamisligil. Inflammation, metaflammation and immunometabolic disorders. *Nature*, 542(7640):177–185, 2017.

[23] Peter Ghazal, Steven Watterson, Kevin Robertson, and David C Kluth. The in silico macrophage: toward a better understanding of inflammatory disease, 2011.

[24] Massimo Locati, Graziella Curtale, and Alberto Mantovani. Diversity, mechanisms, and significance of macrophage plasticity. *Annual Review of Pathology: Mechanisms of Disease*, 15(1):123–147, 2020.

[25] Ewan A Ross, Andrew Devitt, and Jill R Johnson. Macrophages: the good, the bad, and the gluttony. *Frontiers in immunology*, 12:708186, 2021.

[26] Oussema Souiai, Fatma Guerfali, Slimane Ben Miled, Christine Brun, and Alia Benkahla. In silico prediction of protein-protein interactions in human macrophages, 2015.

[27] Xinguo Jiang, Mark R Nicolls, Wen Tian, and Stanley G Rockson. Lymphatic dysfunction, leukotrienes, and lymphedema. *Annual review of physiology*, 80(1):49–70, 2018.

[28] HuiMin Li, Yan Wang, Bin Wang, Min Li, JiPing Liu, HongLian Yang, and YongHeng Shi. Baicalin and geniposide inhibit polarization and inflammatory injury of ogd/r-treated microglia by suppressing the 5-lox/ltb4 pathway. *Neurochemical Research*, 46(7):1844–1858, 2021.

[29] Maryam Bagheri and Mohammadreza Azmoodeh. Substrate stiffness changes cell rolling and adhesion over l-selectin coated surface in a viscous shear flow, 2019.

[30] Kara L Spiller and Timothy J Koh. Macrophage-based therapeutic strategies in regenerative medicine. *Advanced drug delivery reviews*, 122:74–83, 2017.

[31] Debie Anggraini, Dita Hasni, and Rinita Amelia. Pathogenesis of sepsis. *Scientific Journal*, 1(4):334–341, 2022.

[32] Lu-Xi Zheng, Ke-Xin Li, Fen-Fang Hong, and Shu-Long Yang. Pain and bone damage in rheumatoid arthritis: role of leukotriene b4. *Clin Exp Rheumatol*, 37(5):872–878, 2019.

[33] Juan Antonio Giménez-Bastida, Antonio González-Sarrías, Juan Carlos Espín, and Claus Schneider. Inhibition of 5-lipoxygenase-derived leukotrienes and hemiketals as a novel anti-inflammatory mechanism of urolithins. *Molecular nutrition & food research*, 64(11):2000129, 2020.

[34] MohammadAmin Ansari Khoushabar and Parviz Ghafariasl. Advanced meta-ensemble machine learning models for early and accurate sepsis prediction to improve patient outcomes, 2024.

[35] Brenden K. Petersen, Jiachen Yang, Will S. Grathwohl, Chase Cockrell, Claudio Santiago, Gary An, and Daniel M. Faissol. Precision medicine as a control problem: Using simulation and deep reinforcement learning to discover adaptive, personalized multi-cytokine therapy for sepsis, 2018.

[36] Alex R Schuurman, Peter MA Sloot, W Joost Wiersinga, and Tom van der Poll. Embracing complexity in sepsis. *Critical Care*, 27(1):102, 2023.

[37] Wan-Chung Hu. Sepsis is a syndrome with hyperactivity of th17-like innate immunity and hypoactivity of adaptive immunity, 2013.

[38] Ouassim Bara, Seddik Djouadi, Judy Day, and Suzanne Lenhart. Immune therapeutic strategies using optimal controls with l^1 and l^2 type objectives, 2017.

[39] Rico Berner, Jakub Sawicki, Max Thiele, Thomas Löser, and Eckehard Schöll. Critical parameters in dynamic network modeling of sepsis, 2022.

[40] Yuyang Chen, Kaiming Bi, Chih-Hang J. Wu, David Ben-Arieh, and Ashesh Sinha. An improved mathematical model of sepsis: Modeling, bifurcation analysis, and optimal control study for complex nonlinear infectious disease system, 2022.

[41] Fatih Demirci, Ayse Karadag, Sevde Biltekin, and Betül Demirci. In vitro ace2 and 5-lox inhibition of rosmarinus officinalis l. essential oil and its major component 1, 8-cineole. *Records of Natural Products*, 16(2), 2022.

[42] Shiyi Jiang, Xin Gai, Miriam Treggiari, William W. Stead, Yuankang Zhao, C. David Page, and Anru R. Zhang. Soft phenotyping for sepsis via ehr time-aware soft clustering, 2024.

[43] Yueran Yang, Yu Zhang, Shuai Li, Xubin Zheng, Man-Hon Wong, Kwong-Sak Leung, and Lixin Cheng. A robust and generalizable immune-relatedsignature for sepsis diagnostics, 2021.

[44] Kelly Roveran Genga and James A Russell. Update of sepsis in the intensive care unit. *Journal of innate immunity*, 9(5):441–455, 2017.

[45] Todd Gary, Damian Mingle, and Ashwini Yenamandra. The evolving definition of sepsis, 2016.

[46] Jelena Bošković, Vladimir Dobričić, Marija Mihajlović, Jelena Kotur-Stevuljević, and Olivera Čudina. Synthesis, evaluation of enzyme inhibition and redox properties of potential dual cox-2 and 5-lox inhibitors. *Pharmaceuticals*, 16(4):549, 2023.

[47] Kevin Ewig, Xiangwen Lin, Tucker Stewart, Katherine Stern, Grant O'Keefe, Ankur Teredesai, and Juhua Hu. Multi-subset approach to early sepsis prediction, 2023.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.